Results 131 to 140 of about 141,477 (341)

Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test

Clinical Pharmacology &Therapeutics, EarlyView.
There is increasing attention on the clinical utility and value of pharmacogenetic (PGx) testing to individualize medication management. Most clinical practice guidelines from medical professional societies do not recommend routine PGx testing, with a few key exceptions.
James M. Stevenson, D. Max Smith, Sony Tuteja, Jai N. Patel, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +4 more
wiley   +1 more source

Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago

Cardiology and Therapy
Introduction Trinidad & Tobago has the highest prevalence of cardiovascular disease (CVD) in the Caribbean and clopidogrel is a ubiquitously used treatment. Yet, the extent of genetically mediated clopidogrel resistance is unknown.
Daniele Jones, Shana Persad-Ramdeensingh, Sheherazade Crystal Abrahim, Naveen Seecheran, Rajini Rani Haraksingh   +4 more
doaj   +1 more source

Evaluation ofAaspirin, Clopidogrel or Their Combination In Hypertensive Patients

Al-Mustansiriyah Journal of Pharmaceutical Sciences, 2010
The objective of this study is to evaluate the effect of aspirin, clopidogrel or their combination on different parameters in hypertensive patients.
Fadia Y. Al-hamdani, Maitham M. Al-mefraji   +1 more
doaj   +1 more source

Clinical application of high throughput molecular screening techniques for pharmacogenomics. [PDF]

, 2011
Genetic analysis is one of the fastest-growing areas of clinical diagnostics. Fortunately, as our knowledge of clinically relevant genetic variants rapidly expands, so does our ability to detect these variants in patient samples.
Schrijver, Iris, Wiita, Arun P
core   +1 more source

Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study

Circulation. Cardiovascular Interventions, 2019
Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced ...
N. Pereira, C. Rihal, D. So, Y. Rosenberg, R. Lennon, V. Mathew, S. Goodman, R. Weinshilboum, Liewei Wang, L. Baudhuin, A. Lerman, Ahmed A Hasan, E. Iturriaga, Yi-Ping Fu, N. Geller, K. Bailey, M. Farkouh   +16 more
semanticscholar   +1 more source

Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel

Journal of Thrombosis and Thrombolysis, 2020
Platelets aggregation leading to thrombosis plays a pivotal role in the pathophysiology of acute coronary syndrome (ACS) and of stent thrombosis. Antiplatelet therapy with aspirin plus an ADP-receptor inhibitor (ticagrerol, prasugrel or clopidogrel) is ...
P. Cirillo, V. Taglialatela, Grazia Pellegrino, A. Morello, Stefano Conte, L. Di Serafino, G. Cimmino   +6 more
semanticscholar   +1 more source

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges

Clinical Pharmacology &Therapeutics, EarlyView.
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith, Michael P. Douglas, Christina L. Aquilante, Patricia A. Deverka, Beth Devine, Henry M. Dunnenberger, Philip E. Empey, Daniel L. Hertz, Andrew A. Monte, Ann M. Moyer, Jai N. Patel, Victoria M. Pratt, Loren Saulsberry, Stuart A. Scott, Deepak Voora, Erica L. Woodahl, Michelle Whirl‐Carrillo, Akinyemi Oni‐Orisan, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +18 more
wiley   +1 more source

Remote platelet function testing using P-selectin expression in patients with recent cerebral ischaemia on clopidogrel

Stroke and Vascular Neurology
Background Antiplatelet agents reduce recurrence after cerebral ischaemia but are not effective in all patients, in part because of treatment resistance. The primary aim was to assess the proportion of patients who are insensitive to clopidogrel.
Philip M Bath, Nikola Sprigg, Jason Philip Appleton, Carla Richardson, Natalia Dovlatova, Jane May, Stan Heptinstall   +6 more
doaj   +1 more source

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. [PDF]

, 2019
BACKGROUND: Ticagrelor is an oral P2Y12 inhibitor that is used with aspirin to reduce the risk of ischemic events among patients with acute coronary syndromes or previous myocardial infarction.
Arnold, Susan E., Bhatt, Deepak L., Jennings, Lisa K., Lee, John S., Mays, Michael C., Pollack, Charles V., Umstead, Bret R., Weitz, Jeffrey I., Xu, Sherry   +8 more
core   +1 more source

Elevated Baseline Serum Fibrinogen: Effect on 2-Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention. [PDF]

, 2017
BackgroundElevated fibrinogen is associated with short-term major adverse cardiovascular events (MACE) after percutaneous coronary intervention, but the relation with late MACE is unknown.Methods and resultsBaseline demographics and 2-year MACE were ...
Ang, Lawrence, Behnamfar, Omid, Lin, Felice, Mahmud, Ehtisham, Palakodeti, Samhita, Patel, Mitul P, Pourdjabbar, Ali, Reeves, Ryan R   +7 more
core   +1 more source